On October 25, 2023, Appili Therapeutics Inc. (OTC:APLIF) (TSX:APLI.TO) announced that the company secured a commitment for the second stage of funding (US$6.6 million) for ATI-1701 from the U.S. Air ...

ATI Inc. ATI stated that its board of directors has authorized the repurchase of up to $700 million in outstanding common shares, which the company anticipates would support a multi-year share buyback ...

BOLINGBROOK, Ill.--(BUSINESS WIRE)--ATI Physical Therapy (ATI), one of the nation’s largest providers of physical therapy services, today announced the launch of new limb loss specialty centers that ...

Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis Topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the ...